Empagliflozin improves beta cell function independently of relief of glucotoxicity in patients with type 2 diabetes: results from a randomised cross-over study with insulin as comparator
This study was supported by Boehringer Ingelheim. Additional funding was provided by the Grosserer L.F. Foghts Fond, Charlottenlund, Denmark.
Authors
- Roopameera Thirumathyam (ORCID: https://orcid.org/0000-0001-8386-4864)
- Erik A. Richter (ORCID: https://orcid.org/0000-0002-6850-3056)
- Gerrit van Hall (ORCID: https://orcid.org/0000-0002-2519-8127)
- Nils B. Jørgensen (ORCID: https://orcid.org/0000-0002-5764-6377)
- Sten Madsbad (ORCID: https://orcid.org/0000-0002-5017-1815)
- Per Lav Madsen (ORCID: https://orcid.org/0000-0001-8655-4458)
- Nicoline R. Andersen (ORCID: https://orcid.org/0000-0002-1512-2727)
- Jens Juul Holst (ORCID: https://orcid.org/0000-0001-6853-3805)
Institutions
- University of Copenhagen (DK)
- Novo Nordisk Foundation (DK)
- Hvidovre Hospital (DK)
- Gentofte Hospital (DK)
- Rigshospitalet (DK)
- Danish Ministry of Defence (DK)
Publication Details
- Journal
- Diabetologia
- Published
- 2025-12-09
- DOI
- https://doi.org/10.1007/s00125-025-06616-y
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Association for the Study of Diabetes
- Hvidovre Hospital